Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

Last updated: December 11, 2024
Sponsor: Dong-A ST Co., Ltd.
Overall Status: Active - Not Recruiting

Phase

4

Condition

Osteoporosis

Post-menopausal Osteopenia

Treatment

Risedronate Sodium 35 MG [Actonel]

Calcium Vitamin D combination

Clinical Study ID

NCT05630768
ATN_PMO_IV
  • Ages 50-80
  • Female

Study Summary

To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year

Eligibility Criteria

Inclusion

Main Inclusion Criteria:

  1. Postmenopausal women

  2. Patients diagnosed with postmenopausal osteoporosis and administered denosumab for 1year

Exclusion

Main Exclusion Criteria:

  1. Any contraindication to risedronate

  2. Those evaluated as inappropriate at the discretion of the investigator

Study Design

Total Participants: 155
Treatment Group(s): 2
Primary Treatment: Risedronate Sodium 35 MG [Actonel]
Phase: 4
Study Start date:
January 03, 2023
Estimated Completion Date:
July 31, 2025

Connect with a study center

  • Severance Hospital

    Seoul, Seodaemun-gu 03722
    Korea, Republic of

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.